After signing up, you'll start to receive regular news updates from us.
The Wellcome Trust Case Control Consortium Selects Illumina DNA Analysis Products
Complete the form below to unlock access to ALL audio articles.
Illumina, Inc. has announced that researchers participating in a new initiative funded by the Wellcome Trust selected Illumina's Infinium HD BeadChips to analyze 90,000 DNA samples.
This new initiative aims to decipher the molecular basis of human disease and includes participation from leading research groups around the globe.
Together, researchers at the Wellcome Trust Case Control Consortium 2 (WTCCC2) and 12 independent consortia will collect more than 120,000 DNA samples and analyze them for both single nucleotide polymorphisms (SNPs) and copy number variants (CNVs).
This new series of genome-wide association studies are collectively the world's largest genetic research initiative conducted to date, and is expected to uncover genetic variants linked to many diseases such as multiple sclerosis, schizophrenia, and asthma.
In addition to 90,000 samples collected from study participants, 6,000 control samples will be collected and analyzed using Illumina's Infinium HD Human1M-Duo BeadChip.
“Genetic research provides valuable and often unexpected insights into complex diseases, and promises to assist with the development of new and more effective treatments,” said Professor Leena Peltonen, Head of Human Genetics at The Wellcome Trust Sanger Institute and Deputy Chair of the WTCCC2.
Over the next two years, researchers involved with the Wellcome Trust initiative are expected to generate as many as 120 billion pieces of genetic data. Bill Cookson, M.D., Ph.D., and his team at Imperial College London are among 12 independent groups who selected Illumina's HD Infinium BeadChips to analyze DNA samples for genetic variants linked to complex diseases.
